
Sign up to save your podcasts
Or
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
4.3
2323 ratings
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
13 Listeners
323 Listeners
98 Listeners
160 Listeners
863 Listeners
494 Listeners
694 Listeners
18 Listeners
274 Listeners
254 Listeners
3,319 Listeners
135 Listeners
1,084 Listeners
7,960 Listeners
186 Listeners
59 Listeners
8 Listeners
423 Listeners
314 Listeners